Can you take AZO after gastric sleeve surgery? It is an important question for anyone managing urinary discomfort following bariatric surgery. AZO products contain phenazopyridine hydrochloride, a urinary analgesic widely used in the United States — however, phenazopyridine is not licensed in the UK and does not appear in the British National Formulary (BNF). Following sleeve gastrectomy, significant changes to stomach anatomy and drug absorption mean that even seemingly straightforward over-the-counter remedies require careful consideration. This article explores the safety, suitability, and evidence-based alternatives for managing urinary tract symptoms after gastric sleeve surgery.

Taking AZO After Gastric Sleeve Surgery: Key Considerations

AZO (phenazopyridine) is not licensed in the UK and is unavailable on the NHS; post-sleeve gastrectomy patients should consult their bariatric team or GP before taking any new medication, including products obtained from abroad.

Have any more questions about this? Message our pharmaceutical team to get more info →

AZO is a brand name widely recognised in the United States for products containing phenazopyridine hydrochloride, a urinary analgesic used to relieve the pain, burning, and discomfort associated with urinary tract infections (UTIs) and bladder irritation. It is important to note that AZO-branded products are not licensed or available in the UK; phenazopyridine does not hold a UK marketing authorisation and is not listed in the British National Formulary (BNF). Despite this, some patients obtain it online or bring it back from abroad.

Patients are strongly advised not to purchase unlicensed medicines online unless from an MHRA-registered pharmacy. Unregistered online sources carry a significant risk of supplying falsified or substandard products. The MHRA provides guidance on identifying legitimate online pharmacies at gov.uk/mhra.

Following a sleeve gastrectomy (gastric sleeve surgery), patients face significant changes to their digestive anatomy. The stomach is reduced to a small tube — typically around 15–20% of its original volume, though this varies between individuals and surgical technique — which has profound implications for how medications are absorbed, tolerated, and metabolised. Any medication, including over-the-counter remedies such as phenazopyridine, must therefore be considered carefully in the post-operative context.

Patients who have undergone bariatric surgery are generally advised to consult their bariatric surgical team or GP before taking any new medication. This reflects genuine physiological changes that can alter drug efficacy and safety. The sections below explore these considerations in detail.

How Gastric Sleeve Surgery Affects Medication Absorption

Sleeve gastrectomy reduces stomach volume and alters gastric pH and emptying speed, potentially changing drug dissolution, absorption, and bioavailability for all oral medications including phenazopyridine.

Sleeve gastrectomy fundamentally alters the gastrointestinal tract. Unlike gastric bypass, it does not reroute the small intestine, but the dramatic reduction in stomach volume significantly affects how medications are processed. Reduced gastric acid production and faster gastric emptying that may follow surgery can alter the dissolution and absorption of oral medications.

Key pharmacokinetic changes after gastric sleeve surgery include:

• Reduced stomach volume: Less space for tablets or capsules to dissolve properly before entering the small intestine.

• Altered gastric pH: Lower acid levels may impair the breakdown of certain drug formulations.

• Faster gastric emptying: Medications may pass through the stomach more quickly, potentially reducing absorption time.

• Changes in drug bioavailability: Some medications may be absorbed at higher or lower concentrations than expected.

These changes are particularly relevant for modified-release (MR) or enteric-coated formulations, which rely on a specific pH environment or transit time to release their active ingredient appropriately. For this reason, UK bariatric guidance from the British Obesity and Metabolic Surgery Society (BOMSS) and the Specialist Pharmacy Service (SPS) generally recommends immediate-release, liquid, or crushable formulations in the early post-operative period, and advises avoiding modified-release or enteric-coated preparations unless specifically recommended by a clinician.

For phenazopyridine specifically, it is an immediate-release oral tablet absorbed in the gastrointestinal tract. While it is not a modified-release formulation, the altered absorption environment post-sleeve gastrectomy may still influence how consistently and completely it is absorbed, potentially affecting both its therapeutic effect and its side effect profile. Patients should seek advice from their bariatric team or pharmacist before taking any oral medication post-surgery.

Safety and Suitability of Phenazopyridine Post-Surgery

Phenazopyridine carries risks of methaemoglobinaemia, haemolytic anaemia, hepatotoxicity, and renal accumulation — risks that may be heightened after bariatric surgery, particularly in the context of post-operative dehydration.

Phenazopyridine is classified as a urinary tract analgesic rather than an antibiotic. It does not treat the underlying infection but instead numbs the lining of the urinary tract to provide symptomatic relief. In the UK, it is not a licensed medicine and is not recommended by NICE, the NHS, or the MHRA as a standard treatment for UTIs. Its use is therefore already outside mainstream UK clinical guidance, regardless of surgical history.

In countries where phenazopyridine is licensed (such as the United States), it is indicated only for short-term adjunctive use alongside antibiotic treatment — it is not intended as a standalone remedy. This distinction is important: using it without also treating the underlying infection risks masking symptoms while the infection progresses.

From a safety perspective, phenazopyridine carries several known risks that may be amplified following bariatric surgery:

• Methaemoglobinaemia: A potentially serious condition in which haemoglobin is converted to a form unable to carry oxygen effectively; this is a recognised adverse effect, particularly with higher doses or in susceptible individuals.

• Haemolytic anaemia: Particularly in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.

• Hepatotoxicity: Liver toxicity has been reported. Patients with pre-existing liver disease should exercise particular caution.

• Renal impairment risk: The drug is renally excreted, and dehydration — common post-bariatric surgery — could increase the risk of accumulation and toxicity.

• Urine and tear discolouration: Phenazopyridine causes a characteristic orange-red discolouration of urine and may stain contact lenses. Importantly, it can interfere with urine dipstick tests and urinalysis, potentially leading to inaccurate results if a urine sample is taken while the drug is being used.

• Gastrointestinal side effects: Nausea and stomach upset are common and may be more pronounced in a surgically altered stomach.

There is no official clinical guidance specifically addressing phenazopyridine use after gastric sleeve surgery, largely because the drug is not licensed in the UK. Given the above concerns, most bariatric clinicians would advise caution or avoidance until a healthcare professional has been consulted.

If you experience any suspected side effects from phenazopyridine or any other medicine, you can report these to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

Managing Urinary Tract Symptoms After Bariatric Surgery

UTI symptoms after bariatric surgery should be assessed by a GP; NICE NG109 guides antibiotic prescribing, and consistent hydration in line with post-operative advice is an important supportive measure.

Urinary tract infections are relatively common in the general population, and bariatric surgery patients are not immune. Certain post-operative factors — including altered fluid intake habits and changes to urinary tract physiology — may be relevant to urinary health following surgery. (Note: whilst increased urinary oxalate excretion after bariatric surgery is associated with a higher risk of kidney stones, its direct role in increasing UTI risk is less well established.)

If you experience symptoms such as burning on urination, increased urinary frequency, pelvic discomfort, or cloudy and strong-smelling urine, the recommended first step is to contact your GP.

According to NICE guideline NG109 (Urinary tract infection [lower]: antimicrobial prescribing), in many non-pregnant women with uncomplicated lower UTI, empirical antibiotic treatment can be started without routinely sending a midstream urine (MSU) sample first. However, an MSU should be sent in the following situations:

• Pregnancy

• Men

• Children and young people

• Catheter-associated UTI

• Recurrent UTI or treatment failure

• Atypical or severe symptoms

For post-bariatric patients specifically, managing UTI symptoms involves some additional considerations:

• Hydration: Adequate fluid intake is essential but must be balanced carefully post-surgery. Sipping fluids consistently throughout the day (rather than drinking large volumes at once) is standard post-operative advice.

• Antibiotic selection and absorption: For most immediate-release antibiotics, absorption after sleeve gastrectomy is generally adequate. However, the prescribing clinician should be aware of the patient's surgical history, and specialist advice (e.g., from BOMSS or SPS guidance) should be sought if there is any uncertainty.

Self-medicating with unlicensed urinary analgesics is not advisable in this population. Prompt professional assessment ensures both accurate diagnosis and safe, effective treatment.

Alternatives to AZO Recommended After Gastric Sleeve

Paracetamol (preferably liquid or soluble formulation) is the recommended analgesic for symptomatic relief after gastric sleeve surgery; confirmed UTIs should be treated with GP-prescribed antibiotics such as nitrofurantoin or trimethoprim per NICE NG109.

Given that phenazopyridine (AZO) is not licensed in the UK and carries specific risks for post-bariatric patients, it is helpful to understand what safe and evidence-based alternatives are available for managing urinary discomfort.

For symptomatic relief whilst awaiting GP assessment:

• Paracetamol: A well-tolerated analgesic that can help manage pain and discomfort. It is generally considered safe after gastric sleeve surgery when taken in standard doses, though patients should not exceed recommended limits. Liquid or soluble formulations may be preferable, particularly in the early post-operative period.

• Increased fluid intake: Drinking more water can help flush the urinary tract and dilute urine, reducing irritation. This should be done gradually and in line with post-operative hydration guidance.

• Avoiding bladder irritants: Caffeine, alcohol, and spicy foods can worsen urinary symptoms and should be minimised.

• NSAIDs (e.g., ibuprofen): These should generally be avoided after bariatric surgery due to the increased risk of gastric ulceration and anastomotic complications, unless specifically recommended by a clinician (with appropriate gastroprotection such as a proton pump inhibitor if used). Seek advice from your GP or bariatric team before taking any NSAID.

For confirmed UTIs, GP-prescribed treatments include (per NICE NG109):

• Nitrofurantoin: First-choice antibiotic for uncomplicated lower UTI in adults where eGFR is ≥45 mL/min/1.73 m².

• Trimethoprim: An alternative first-choice option where the risk of resistance is low (e.g., not used in the previous 3 months, low local resistance rates, or guided by culture results).

• Pivmecillinam or fosfomycin: Alternative options recommended in NG109, particularly useful where resistance or tolerability is a concern.

Antibiotic choice should always be guided by local resistance patterns, culture results where available, and individual patient factors including renal function.

It is worth noting that cranberry products are sometimes used as a preventative measure, though NICE does not recommend them as a treatment for active UTIs. Any preventive use should be discussed with a clinician, as some formulations contain sugars or compounds that may not be suitable after bariatric surgery.

When to Seek Advice From Your Surgical or GP Team

Post-bariatric patients should contact their GP promptly for any urinary symptoms and seek urgent care if fever, rigors, or flank pain develop, as these may indicate pyelonephritis requiring immediate treatment.

Following gastric sleeve surgery, the threshold for seeking professional medical advice should be lower than it might have been before surgery. This is not a cause for alarm, but rather a reflection of the fact that your body processes medications and responds to illness differently after bariatric surgery.

Contact your GP promptly if you experience:

• Burning, stinging, or pain when urinating

• Frequent or urgent need to urinate

• Cloudy, dark, or strong-smelling urine

• Lower abdominal or pelvic pain

• Fever, chills, or back/flank pain (which may suggest a kidney infection requiring urgent treatment)

Certain groups should seek prompt GP assessment and an MSU, including those who are pregnant, male, using a urinary catheter, immunosuppressed, have urological abnormalities, or have a history of recurrent UTIs. These presentations require more careful assessment in line with NICE NG109.

Contact your bariatric surgical team or GP before taking any new medication, including over-the-counter products, herbal remedies, or supplements. This includes phenazopyridine or any AZO-branded product obtained from abroad or online. Your team can advise on safe formulations, appropriate doses, and whether a particular medication is suitable given your surgical history.

Seek urgent medical attention or call NHS 111 if you develop high fever, rigors, vomiting, or severe flank pain, as these may indicate pyelonephritis (kidney infection), which requires prompt antibiotic treatment and possibly hospitalisation. If you are very unwell, call 999 or go to your nearest emergency department.

In summary, whilst the desire to manage urinary discomfort quickly and independently is understandable, post-bariatric patients benefit most from a cautious, informed approach. The NHS and your bariatric team are well-placed to provide safe, personalised guidance — and early intervention almost always leads to better outcomes than self-treatment with unlicensed or potentially unsuitable medications.

Frequently Asked Questions